NFG
SPRY icon

Nations Financial Group’s ARS Pharmaceuticals SPRY Stock Holding History

Nations Financial Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,000
Closed -$71.6K – 642
2023
Q1 		$71.6K Buy
+11,000
New +$84.5K 0.01% 604

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nations Financial Group's SPRY Position: Q2 2023 in Review

Nations Financial Group sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 11,000 shares — an estimated $71.6K sold.

Nations Financial Group first reported a position in SPRY in Q1 2023 and held it in 1 quarter. The position peaked at $71.6K in Q1 2023. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

  • Nations Financial Group reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Nations Financial Group sold 11,000 ARS Pharmaceuticals shares in Q2 2023, an estimated $71.6K.
  • Nations Financial Group first reported a position in ARS Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Nations Financial Group's ARS Pharmaceuticals position peaked at $71.6K in Q1 2023.
  • 92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on Nations Financial Group's 13F filing for Q2 2023, filed 14 Aug 2023.